Co-Diagnostics, Inc. Adds to Menu of Molecular Vector Control Products
10 Octubre 2019 - 5:30AM
Co-Diagnostics, Inc.
(Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today the
product launch of their Vector Smart™ ZDC test, used to identify
the presence of Zika, dengue, and chikungunya in mosquito
populations, in response to demand from domestic and foreign
markets.
The Vector Smart ZDC multiplex test was created
following requests from mosquito abatement districts and ministries
of health throughout North America, Latin America and the Caribbean
for a test that can accurately identify Zika, dengue and
chikungunya, but which is tailored specifically for mosquito
populations. Most polymerase chain reaction (PCR) assays used for
mosquito testing were designed and validated for use on human
samples. The Company’s Vector Smart line of PCR products are
validated using extractions from mosquito samples rather than
humans and include an extraction control specifically for
mosquitoes, to reduce the possibility of a false negative result
due to an improper extraction.
Dwight Egan, CEO of Co-Diagnostics, commented,
“Our mosquito abatement vertical began generating revenue earlier
this year and is expected to continue to grow in several markets.
The Vector Smart ZDC test in particular was developed in response
to interest from both domestic and international regions where it
is in high demand.
“Testing mosquito populations is one of the
primary lines of defense against the proliferation of
mosquito-borne illnesses. Co-Diagnostics’ highly specific and
sensitive CoPrimer™-based Vector Smart products help abatement
activities to be more effective and provide a shield against
diseases entering and spreading across non-endemic regions,
including the US.”
The Company’s Logix Smart™ ZDC Test, which
received CE-IVD approval earlier this year, served as a template
for the initial design and development of the new Vector Smart
product. Also in development is another multiplex product for North
America that includes eastern equine encephalitis (EEE), a rare
cause of brain infections that has been identified at a
significantly higher occurrence than normal this year. EEE has a
high mortality rate of roughly 30%, and a high percentage of
survivors have ongoing neurological problems as well.
More information about the Company’s vector
control solutions, pricing for the laboratory equipment packages,
and tests currently available or in development can be found on the
Company’s website at
http://codiagnostics.com/products/vector-solutions/.
About Co-Diagnostics,
Inc.:Co-Diagnostics, Inc., a Utah corporation, is a
molecular diagnostics company that develops, manufactures and
markets a new, state-of-the-art diagnostics technology. The
Company’s technology is utilized for tests that are designed using
the detection and/or analysis of nucleic acid molecules (DNA or
RNA). The Company also uses its proprietary technology to design
specific tests to locate genetic markers for use in industries
other than infectious disease and license the use of those tests to
specific customers.
Forward-Looking Statements:
This press release contains
forward-looking statements. Forward-looking statements can be
identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company’s liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company’s products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company’s balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities
laws.
Company
Contact:
Andrew
Benson
Head of Investor
Relations
+1
801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Co Diagnostics (NASDAQ:CODX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024